Panelist: Policy And Perception
Conversation followed by audience Q+A
How does a vision become reality and what role does public perception play when shaping policy? How does end-of-life care fit into the broader landscape of psychedelic policy reform? Learn from lawyers and advocates, Graham Boyd and Hadas Alterman, and physician, Sunil K. Aggarwal, about the strategies and resources needed to move psychedelic medicines safely into mainstream modalities of care.
More about Sunil
Sunil Aggarwal, MD, PhD, FAAPMR, is a board-certified physician in hospice and palliative medicine and physical medicine and rehabilitation as well as a medical geographer; and serves as the past chair of the American Academy of Hospice and Palliative Medicine (AAHPM) Integrative Medicine Special Interest Group as well as an inaugural member of AAHPM’s Safe Use in Psychedelic-Assisted Therapies Forum. Dr. Aggarwal was named as a Top 20 Emerging Leader by the AAHPM. He is a Voluntary Assistant Clinical Professor in Rehabilitation Medicine at the University of Washington School of Medicine, an Affiliate Assistant Professor in the Department of Geography, and an Affiliate Clinical Faculty with Bastyr University. Dr. Aggarwal completed his MD and PhD degrees at the University of Washington and completed his Residency and Fellowship at Virginia Mason Medical Center, NYU Langone Health, and the NIH Clinical Center Pain and Palliative Care Service. He is a Co-Founder, Co-Director and Practitioner at the Advanced Integrative Medical Science (AIMS) Institute in Seattle, a multi-specialty teaching clinic and research institute offering cutting edge care in oncology, psychiatry, neurology, rehabilitation, pain, and palliative care. Dr. Aggarwal also serves as an Associate Hospice Medicine Director and On-Call Palliative Physician for MultiCare Health System. A former National Science Foundation Graduate Research Fellow, Dr. Aggarwal completed his PhD dissertation on “The Medical Geography of Cannabinoid Botanicals in Washington State: Access, Delivery, and Distress.” He is presently a co-investigator on the AIMS Cancer Outcomes Study, the AIMS Medical Outcomes Study, and the Canadian Psilocybin Safety Initiative Registry. He has published over three dozen peer-reviewed articles and book chapters and is honored to serve as a member of the Board of Directors of End of Life Washington and the Center for the Study of Cannabis and Social Policy.